04THERAPEUTIC R&D
NEXT-GENERATION AAV
Next-generation AAV
for kidney diseases
Vector engineering and in-vivo screening support gene-therapy research in kidney diseases, with emphasis on candidate-vector discovery and validation.
01Vector engineering
Designing and screening candidate vectors for kidney diseases.
02Disclosure boundary
Specific receptors, capsid sequences and detailed delivery mechanisms are undisclosed.
03Animal validation
Animal validation data have been obtained in a hereditary kidney disease program.